Document is current
Any future updates will be listed below
-
Authors
Soupir, Alex https://orcid.org/0000-0003-1251-9179
Ospina, Oscar E.
Hampton, Oliver https://orcid.org/0000-0001-9164-1070
Churchman, Michelle https://orcid.org/0000-0002-6560-1056
Radmacher, Michael
Hedges, Dale
McKean, David
Agius, Phaedra
Zeeshan, Saman
Seligson, Nathan D. https://orcid.org/0000-0002-9670-3792
Pollock, Raphael https://orcid.org/0000-0002-0443-1583
Liebner, David
Chen, James L.
Tinoco, Gabriel
Salhia, Bodour
McCarter, Martin https://orcid.org/0000-0001-8174-1713
Wilky, Breelyn A.
Miller, Benjamin J.
Cavnar, Michael J.
Groundland, John S.
Schneider, Bryan P. https://orcid.org/0000-0003-1868-7739
Riedlinger, Gregory
Edge, Stephen B.
Moskaluk, Christopher A.
Cardona, Kenneth
Naqash, Abdul Rafeh
Gonzalez, Ricardo J.
Mullinax, John E.
Joyce, David M. https://orcid.org/0000-0003-0042-4367
Binitie, Odion https://orcid.org/0000-0002-2674-9939
Douglas Letson, G. https://orcid.org/0000-0001-5344-4316
Naghavi, Arash O.
Druta, Mihaela
Reed, Damon R. https://orcid.org/0000-0002-8238-2465
Siegel, Erin M. https://orcid.org/0000-0003-1779-2510
Teer, Jamie K. https://orcid.org/0000-0003-4513-0282
Fridley, Brooke L. https://orcid.org/0000-0001-7739-7956
Brohl, Andrew S. https://orcid.org/0000-0002-0071-0534
-
Funding
Funding for this research was provided by:
AmandaLee Sarcoma Fund, Moffitt Cancer Center
- License Information
-
More Information
Article History
Received: 7 May 2024
Accepted: 24 March 2025
First Online: 6 May 2025
Competing interests
: O.H., M.C., M.R., D.H., D.M., P.A. and S.Z. are or were employed by Aster Insights. E.S. received research funding from the ORIEN Foundation. D.L. – advisory board with Aadi Biosciences and patent licensing (US 10,65,347 B2: Method for Predicting Prognosis) with MatchTx, Inc. J.L.C. is an employee of Tempus. G.T. - advisory board with SynOx, Deciphera, Daiichi Sankyo. B.A.W. – consulting or advisory role with Deciphera, Epizyme, Adcendo, Polaris, Boehringer Ingelheim, research funding from Exelixis, and travel expenses from Agenus. G.R. – advisory board with AstraZeneca. A.R.N. – advisory board with Foundation Medicine and NGM biosciences, travel compensation from Foundation Medicine and Caris Life Sciences, D.R.R. – data safety monitoring committee for Eisai and Springworks. M.D. – consulting AdaptImuune, Deciphera, and Aaid Biosciences. A.S.B – advisory board with Deciphera, research funding (institution) from Merck. The remaining authors declare no competing interests.
